Research programme: dopamine D3 receptor antagonists - GlaxoSmithKline

Drug Profile

Research programme: dopamine D3 receptor antagonists - GlaxoSmithKline

Alternative Names: SB-277011; SB-277011A; SB-414796

Latest Information Update: 18 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antipsychotics; Smoking cessation therapies; Tetrahydroisoquinolines
  • Mechanism of Action Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Drug abuse; Schizophrenia; Smoking withdrawal

Most Recent Events

  • 18 Apr 2011 No development reported - Preclinical for Drug abuse in United Kingdom (unspecified route)
  • 18 Apr 2011 No development reported - Preclinical for Schizophrenia in United Kingdom (unspecified route)
  • 18 Apr 2011 No development reported - Preclinical for Smoking withdrawal in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top